(Q33390353)

26 July 2017

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma (English)

1 reference

26 July 2017

phase II clinical trial

0 references

1 reference

Greg Dueck

1

1 reference

26 July 2017

Neil Chua

2

1 reference

26 July 2017

Angeli Prasad

3

1 reference

26 July 2017

Daygen Finch

4

1 reference

26 July 2017

Doug Stewart

5

1 reference

26 July 2017

Darrell White

6

1 reference

26 July 2017

Richard van der Jagt

7

1 reference

26 July 2017

James Johnston

8

1 reference

26 July 2017

Andrew Belch

9

1 reference

26 July 2017

Tony Reiman

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

26 July 2017

1 reference

26 July 2017

116

1 reference

26 July 2017

4541-4548

1 reference

26 July 2017

19

1 reference

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

26 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Natural killer-cell malignancies: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Lenalidomide--the phoenix rises.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Treatment of refractory T-cell malignancies using gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25377

7 January 2021

Identifiers

DOI

10.1002/CNCR.25377

1 reference

26 July 2017

1 reference